Abeona Therapeutics Inc ( (ABEO) ) has released its Q2 earnings. Here is a breakdown of the information Abeona Therapeutics Inc presented to its investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing cell and gene therapies for life-threatening diseases, with a notable product, ZEVASKYN™, approved for treating recessive dystrophic epidermolysis bullosa. In its latest earnings report for the quarter ended June 30, 2025, Abeona Therapeutics highlighted a significant financial turnaround, driven by the FDA approval of ZEVASKYN™ and the sale of a Priority Review Voucher. The company reported a net income of $108.8 million, a substantial increase from a net loss of $24.2 million in the same period last year, largely due to a $152.4 million gain from the sale of the voucher. Abeona’s cash and cash equivalents surged to $163.5 million from $23.4 million at the end of 2024, reflecting improved liquidity. Despite increased expenses in research and development and selling, general, and administrative areas, the company’s financial position strengthened significantly. Looking ahead, Abeona Therapeutics aims to leverage its enhanced financial position to advance its pipeline of gene therapies and expand its manufacturing capabilities, positioning itself for future growth in the biopharmaceutical sector.